FDA Panel Backs First Radio-Frequency Asthma Treatment
By wchung | 08 Jul, 2026
Federal health advisers are recommending a novel technology from Asthmatx be approved as the first non-drug treatment for asthma.
The Food and Drug Administration’s panel of respiratory device experts voted 6-1 that Asthmatx’s Alair System be approved under certain conditions, including long-term tracking of patients.
The company’s procedure, called thermoplasty, uses extreme heat to burn away lung tissue that makes it difficult to breath and causes coughing spasms and wheezing. The heat is delivered via a catheter that emits radiofrequency waves, dissolving excess muscle.
While roughly 20 million people in the U.S. suffer from asthma, thermoplasty would only be appropriate for about 2 million adults who don’t get relief from existing drugs.
10/28/2009 5:06 PM WASHINGTON (AP)
Recent Articles
- China Becomes Innovation Engine for Top Global Legacy Carmakers
- Big Tech Data Centers Drive Up Power Bills at America's Rust Belt Factories
- AstraZeneca Pays $200 Mil. Upfront to License Chinese COPD Drug
- Korean Chip Stocks Rebound from Overnight US Selloff as Chip Supply Remains Tight
- DeepSeek Developing AI Chip in Possible Setback for Majors
- Eala and Osaka’s Wimbledon Upsets, Sudo Retains Belt, MLB All-Star Watch
- China Gold Reserves Rise Most Since 2023 As Bullion Tumbles
- Italy's Meloni Seeks to Avoid Escalation After Trump Revives Personal Feud
- Canada's May Trade Surplus Surged to 4-Year High on US Exports
- Beijing Mulls Curbing Overseas Access to China's Top AI Models
